Infectious Disease Therapeutics Market Likely To Reach A Valuation Of Around USD 86.2 Billion By 2025:Key Participant Janssen Pharmaceutical, Inc., F. Hoffmann-La Roche Ltd.

San Francisco, 31 December 2018,  Infectious Disease Therapeutics Market Analysis By Disease Type (HIV infection, Influenza, Malaria, Tuberculosis, Hepatitis, and HPV infection), By Region, And Segment Forecasts, 2018 – 2025.

The global top6 infectious disease therapeutics market is expected to reach USD 86.2 billion by 2025, according to a new report by Grand View Research, Inc. The market is primarily driven by increasing number of Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), TB, and hepatitis cases globally.

Government and private organizations are investing heavily in the healthcare sector to prevent, diagnose, and treat infectious diseases; rising investments for development of new drugs to treat infectious diseases, and increasing number of initiatives for creating awareness about these conditions are expected to boost the market during the forecast period. Furthermore, increasing number of patent expirations and entry of generic drugs in the market are expected to increase the demand for infectious disease therapeutics due to their low prices.

In addition, availability of reimbursement for diagnosis & treatment of these infections and free distribution of drugs by manufacturers in regions with high incidence of these diseases are factors further expected to propel the market growth. However, low penetration rate of anti-infective and availability of large number of counterfeit drugs are expected to restraint the market growth during the forecast period.

North American market held the largest share in 2016. Presence of large number of manufacturers, favorable reimbursement scenario, and increasing healthcare expenditure are major factors responsible for the largest share held by this region. However, Asia Pacific is likely to grow at the highest rate between 2017 and 2025. High prevalence of infectious diseases; improving economic conditions in Asian countries, rising government initiatives to increase the adoption of treatments for infectious diseases, and rising funding activities are factors that can be attributed for the highest growth rate of this region during the forecast period.

Access Full Research Report On Infectious Disease Therapeutics Market Analysis:www.grandviewresearch.com/industry-analysis/infectious-disease-therapeutics-market

Further Key Findings From the Report Suggest:

·         The HIV therapeutics segment held the largest revenue share in 2016 due to high number of HIV cases globally

·         North America dominated the global market owing to the strong reimbursement framework coupled with high adoption rate of treatments for infectious diseases

·         The HPV therapeutics segment is estimated to grow at the highest rate during the forecast period

·         Some of the key players areNovartis AG, Gilead, GlaxoSmithKline plc, Janssen Pharmaceutical, Inc., F. Hoffmann-La Roche Ltd., BioCryst Pharmaceuticals, Inc., and Boehringer Ingelheim GmbH

Browse More Reports Of This Category By Grand View Research At:  www.grandviewresearch.com/industry/medical-devices

Grand View Research has segmented the top 6 infectious disease therapeutics market on the basis of disease type and region:

Disease Type Outlook (Revenue, USD Million, 2014 - 2025)

·         HIV

o    Emtriva

o    Aptivus

o    Isentress

o    Lexiva/Telzir

o    Selzentry

o    Tivicay 

o    Atripla

o    Complera

o    Genvoya

o    Odefsey

o    Stribild

o    Truvada

o    Triumeq

o    Descovy

o    Vitekta

o    Others

·         Influenza

o    Relenza

o    Tamiflu 

o    Rapivab 

o    Others

·         TB

o    Sirturo

o    Others

·         Malaria

o    Coartem

o    Others

·         HPV

·         Hepatitis

Regional Outlook (Revenue, USD Million, 2014 - 2025)

·         North America

o    U.S.

o    Canada

·         Europe

o    Germany

o    UK

·         Asia Pacific

o    China

o    Japan

·         Latin America

o    Brazil

o    Mexico

·         Middle East & Africa

o    South Africa

Access Full Press Release of this Report:

www.grandviewresearch.com/press-release/global-infectious-disease-therapeutics-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com/

Digital Dose Inhaler Market Expected To Trigger A Revenue Increase To USD 3.56 Billion By 2024:Key Participant Glenmark Pharmaceuticals Ltd., Novartis Digital Dose

San Francisco, 24 December 2018, Digital Dose Inhaler Market Analysis By Product (Metered Dose Inhaler, Dry Powder Inhaler), By Type (Branded Medication, Generics Medication) And Segment Forecasts to 2024

The global digital dose inhaler market is anticipated to reach a value of USD 3.56 billion by 2024, according to a new report by Grand View Research, Inc. The key factors contributing to the lucrative growth of this market include the continually increasing elderly population and the surging prevalence of chronic respiratory diseases.

As a result of impactful economic developments in the fast emerging countries, such as China, India, Brazil, Philippines, and others, there has been growth in the per capita income, which is thus expected to influence the demand for the technologically advanced respiratory devices. Moreover, these technology-enabled respiratory devices are greatly sought after among the pediatric and the geriatric population so as to improve the patient medication compliance, dose tracking, and to enhance patient-healthcare practitioner connectivity that would enable real-time tracking of healthcare data; these serve as high impact rendering factors, significantly driving the market growth in the next nine years.

In order to cater to the unmet needs of the target population, the vendors are expanding their production units and in addition, targeting the niche areas where the prevalence of chronic lung diseases and asthma are on the rise, such as Asia Pacific and MEA regions, to ensure long-term growth and profitability. Therefore, the aforementioned, business expansion trends are expected to boost the usage rates of the digital dose inhalers over the forecast period.

Additionally, favorable government initiatives, such as the introduction of Fixed Dose Combination (FDC), advanced by the U.S. FDA, fast increasing adoption of generic drugs, and the growing demand for digital health platforms are the identified crucial determinants influencing the rapid uptake of these digital inhalers, which is expected to continue in the coming years.

Rapidly increasing geriatric population worldwide in conjunction with the growing prevalence of various chronic respiratory conditions, such as chronic sleep apnea, asthma, COPD, among others negatively impact healthcare system. This would further escalate the demand for innovative respiratory devices thereby encouraging the digital dose inhalers market growth during the forecast period.

Access Full Research Report On Digital Dose Inhaler Market  Analysis:
www.grandviewresearch.com/industry-analysis/digital-dose-inhaler-market

Further key findings from the study suggest:

·         In 2015, the metered dose inhalers (MDIs) segment accounted for the maximum revenue of USD 563.9 million, mainly on account of the increased preference for MDIs.

·         However, the dry powder inhalers (DPIs) segment is expected to emerge as the fastest growing category with a CAGR of 16.9% over the forecast period owing to the growing awareness regarding the adverse effects of chlorofluorocarbons employed as a propellant in the MDIs. Moreover, widespread incidences of drug irritation due to MDI and rising awareness regarding the benefits of using DPIs over MDIs are the leading factors expected to further drive the usage rates of DPIs over the forecast period.

·         In 2015, the branded medication respiratory devices category accounted for the largest market share of USD 747.6 million attributable to the steadily growing need for advanced respiratory drugs and the awareness related to the benefits of combination medication gaining prominence.

·         North America held the maximum share of over 38.64% in 2015. This large share is attributed to the presence of several medical device players in this region, such as Johnson & Johnson, Cohera Medical, Inc., Teleflex Medical, Inc., Covidien Plc, and others. There are over 6,000 medical device companies domiciled in this region, which majorly consists of small and medium sized enterprises (SMEs). Moreover, the soaring geriatric population count and the surging prevalence of chronic respiratory diseases, such as asthma and COPD, are few factors, among others, expected to positively reinforce the digital dose inhaler market over the forecast period.

·         The Asia Pacific (APAC) region is anticipated to grow at a lucrative pace with a CAGR of 17.2% over the forecast period. The upsurge in the healthcare expenditure and the increasing number of U.S. FDA manufacturing sites in APAC countries, such as in China and India, are expected tosignificantly impact the market penetration of the digital dose inhalers.

·         Furthermore, the growing awareness regarding the various innovative technologies employed in the respiratory devices, the ongoing favorable government initiatives that further encourage the use of generic drugs, various subsidies for electronic component manufacturing of medical devices, and several tax benefits that enable medical device exports from this region are anticipated to strongly reinforce the market growth over the forecast period.

·         Some leading players of the market include Glenmark Pharmaceuticals Ltd., Novartis AG, Propeller Health, AstraZeneca Plc, Philips Respironics, Opko Health, Inc., and Teva Pharmaceuticals Industries Ltd.

Browse More Reports Of This Category By Grand View Research At:  www.grandviewresearch.com/industry/medical-devices

Grand View Research has segmented the digital dose inhaler market by product and region:

Digital Dose Inhaler Market Product Outlook (Market revenue in USD Million, 2013 - 2024)

·         Metered dose inhalers

·         Dry powder inhalers

Digital Dose Inhaler Market Type Outlook (Market revenue in USD Million, 2013 - 2024)

·         Branded medication

·         Generic medication

Digital Dose Inhaler Market Regional Outlook, (Market Revenue in USD Billion, 2013 - 2024)

·         North America

o    U.S.

o     Canada

·         Europe

o    Germany

o     UK

·         Asia Pacific

o    Japan

o     China

·         Latin America

o    Brazil

o     Mexico

·         MEA

o    South Africa

Access Full Press Release of this Report:
www.grandviewresearch.com/press-release/global-digital-dose-inhaler-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com/

Cystic Fibrosis Therapeutics Market Expected To Trigger A Revenue Increase To USD 13.9 Billion By 2025:Key Participant AbbVie Inc., F. Hoffmann-La Roche Ltd.

San Francisco, 24 December 2018,  Cystic Fibrosis (CF) Therapeutics Market Analysis By Drug Class (Pancreatic Enzyme Supplements, Mucolytics, Bronchodilators, CFTR Modulators), By Route of Administration, By Region, And Segment Forecasts, 2018 - 2025

The global cysticfibrosis therapeutics market is expected to reach USD 13.9 billion by 2025, according to a new report by Grand View Research, Inc. The rising prevalence of Cystic Fibrosis (CF) globally, research & development activities undertaken by key players, and favorable initiatives undertaken by nonprofit organizations are expected to boost the market over the forecast period.

The rising prevalence of CF indicates the rising demand for treatment alternatives, thereby uplifting the market. The key players operating in this market in collaboration with nonprofit organizations focus on the development of novel therapeutics for treatment. Some of the drugs that are under clinical studies are VX-445 + tezacaftor + ivacaftor, PTI-428, QR-010, AZD5634, and POL6014.

Favorable initiatives taken by regional and national nonprofit organizations is one of the key factors propelling growth. These initiatives ensure support to CF patients. These organizations aid in research & development activities of these therapeutics and help improve the quality of life of these patients. For instance, North American Cystic Fibrosis Conference (NACFC) was formed in 1986 to provide a collaborative and educational forum to CF professionals to share advances in R&D related to CF therapeutics.

Access Full Research Report On Cystic Fibrosis (CF) Therapeutics Market  Analysis:
www.grandviewresearch.com/industry-analysis/cystic-fibrosis-cf-therapeutics-market

Further key findings from the report suggest:

·         The global CF therapeutics market size was estimated at USD 3,560.5 million in 2016 and is expected to grow at a CAGR of 16.7% from 2017 to 2025

·         The CFTR modulator segment emerged as the largest segment in 2016 and the same segment is anticipated to witness fastest growth over the next 8 years owing to the approval of CFTR modulator, Orkambi and the presence of various investigational compounds under the pipeline.

·         Oral route of administration emerged as the largest segment with revenue of USD 2,266.4 million due to the ease of administration and convenience

·         North America accounted for the largest market share owing to the presence of Caucasian descents in this region. Improved healthcare infrastructure, reimbursements, and initiatives undertaken by the nonprofit organizations is expected to propel the market over forecast period,

·         The key players include AbbVie Inc., F. Hoffmann-La Roche Ltd.; Gilead, Novartis AG, Vertex Pharmaceuticals Inc., AIT (Advanced Inhalation Therapies), Alaxia, Teva Pharmaceutical Industries Ltd, Merck & Co. Inc., Alcresta Therapeutics Inc., Allergan, and AstraZeneca

Browse More Reports Of This Category By Grand View Research At:  www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the cystic fibrosis therapeutics market on the basis of drug class, route of administration and region:

Cystic Fibrosis Therapeutics Drug Class Outlook (Revenue, USD Million, 2014 - 2025)

·         Pancreatic enzyme supplements

·         Mucolytics

·         Bronchodilators

·         CFTR modulators

Cystic Fibrosis Therapeutics Route of Administration Outlook (Revenue, USD Million, 2014 - 2025)

·         Oral drugs

·         Inhaled drugs

Cystic Fibrosis Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025)

·         North America

o    U.S.

o    Canada

·         Europe

o    Germany

o    UK

·         Asia Pacific

o    China

o    Japan

·         Latin America

o    Brazil

o    Mexico

·         Middle East & Africa

o    South Africa

Access Full Press Release of this Report:
www.grandviewresearch.com/press-release/global-cystic-fibrosis-cf-therapeutics-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For more information: www.grandviewresearch.com/